Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $26,494.65 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 40,761 shares of the business’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $0.65, for a total transaction of $26,494.65. Following the transaction, the director owned 2,413,158 shares in the company, valued at approximately $1,568,552.70. This represents a 1.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Luke Evnin also recently made the following trade(s):

• On Wednesday, January 7th, Luke Evnin sold 11,915 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total value of $7,625.60.
• On Monday, January 5th, Luke Evnin sold 18,378 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total value of $11,761.92.
• On Friday, January 2nd, Luke Evnin sold 18,568 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $11,697.84.
• On Wednesday, December 31st, Luke Evnin sold 24,962 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.62, for a total value of $15,476.44.
• On Tuesday, December 30th, Luke Evnin sold 34,847 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.61, for a total value of $21,256.67.
• On Monday, December 29th, Luke Evnin sold 108,606 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.61, for a total value of $66,249.66.
• On Friday, December 26th, Luke Evnin sold 35,632 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total value of $22,448.16.
• On Wednesday, December 24th, Luke Evnin sold 16,310 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.65, for a total transaction of $10,601.50.
• On Tuesday, December 23rd, Luke Evnin sold 71,428 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total transaction of $44,999.64.
• On Monday, December 22nd, Luke Evnin sold 59,307 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.69, for a total transaction of $40,921.83.

Werewolf Therapeutics Stock Performance

Shares of HOWL opened at $0.60 on Friday. The company’s fifty day moving average is $0.89 and its 200-day moving average is $1.25. Werewolf Therapeutics, Inc. has a 12 month low of $0.56 and a 12 month high of $2.38. The firm has a market cap of $29.29 million, a price-to-earnings ratio of -0.37 and a beta of 0.77. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.03. Equities analysts expect that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of HOWL. Quadrature Capital Ltd acquired a new stake in shares of Werewolf Therapeutics in the second quarter worth $28,000. Qube Research & Technologies Ltd acquired a new position in Werewolf Therapeutics during the 2nd quarter valued at $48,000. AQR Capital Management LLC bought a new stake in Werewolf Therapeutics in the 1st quarter valued at $79,000. Y Intercept Hong Kong Ltd acquired a new stake in Werewolf Therapeutics in the 2nd quarter worth $92,000. Finally, Bridgeway Capital Management LLC grew its position in Werewolf Therapeutics by 157.7% in the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after purchasing an additional 62,414 shares during the last quarter. 64.84% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

HOWL has been the topic of a number of analyst reports. Zacks Research lowered Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. HC Wainwright lowered their price target on Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, December 19th. Citizens Jmp cut shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, December 19th. Finally, Bank of America decreased their price objective on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Three investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $3.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.